Technical Breakout from Gilead Sciences Inc (GILD)
Biotech Gilead Sciences Inc (GILD) is breaking out technically which made a six-month high today with a +5% gap-up.
The press release of Gilead to Acquire Remaining Worldwide Rights of Trodelvy could be a triggering event. The breast cancer drug from Trodelvy is already in the process of FDA approval for overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy.
Its technical breakout pattern offers an ideal entry point and sell-stop as shown.
